Literature DB >> 1274672

Anticonvulsant osteomalacia determined by quantitative analysis of bone changes. Population study and possible risk factors.

L Mosekilde, F Melsen.   

Abstract

Material has been obtained by biopsy from the right iliac crest of 60 adult epileptic out-patients receiving chronic anticonvulsant therapy with diphenylhydantoin (DPH), either in single-drug or combined-drug regime, and of 16 controls with the same distribution by sex and age. Four (7%) of the epileptics were hypocalcemic and 25 (42%) had elevated serum alkaline phosphatase values. A quantitative analysis of the morphological bone changes was performed on decalcified and undecalcified bone, using integrating filters and the point count principle. An increased amount of unmineralized bone was found in 32 (53%) of the epileptics. The trabecular osteoclastic resorption surfaces and the mean volume of periosteocytic lacunae were increased in 36 (69%) and 45 (75%) patients, respectively. The calcification rate was decreased in relation to what is referred to elsewhere as normal. The bone changes suggest a mineralization defect analogous to osetomalacia with secondary hyperparathyroidism. An increased osteoid volume or thickness and decreased calcification rate were correlated to low dietary vitamin D intake, low exposure to sunlight, high hepatic clearance rate of DPH, combined-drug treatment and the male sex. These parameters should be considered risk factors of anticonvulsant osteomalacia.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1274672     DOI: 10.1111/j.0954-6820.1976.tb06747.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  11 in total

1.  Bone morphology in epileptics.

Authors:  O Johnell; B E Nilsson; A Wallöe; P E Wiklund
Journal:  Calcif Tissue Int       Date:  1979-10-31       Impact factor: 4.333

2.  Anticonvulsant osteomalacia.

Authors: 
Journal:  Br Med J       Date:  1976-12-04

3.  Factors associated with the biochemical changes in vitamin D and calcium metabolism in institutionalized patients with epilepsy.

Authors:  H Gough; A Bissesar; T Goggin; D Higgins; M Baker; M Crowley; N Callaghan
Journal:  Ir J Med Sci       Date:  1986-06       Impact factor: 1.568

Review 4.  The risk-benefit ratio of anticonvulsant drugs.

Authors:  M J Eadie
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Sep-Oct

Review 5.  Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications.

Authors:  A M Pack; M J Morrell
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

6.  [The frequency of adult anticonvulsant osteomalacia in relation to duration of therapy and dosage of anticonvulsants (author's transl)].

Authors:  U Mehregan; K H Krause; P Prager
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1979-04-12

Review 7.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

8.  Fracture incidence and bone disease in epileptics receiving long-term anticonvulsant drug treatment.

Authors:  O S Nilsson; T S Lindholm; E Elmstedt; A Lindbäck; T C Lindholm
Journal:  Arch Orthop Trauma Surg       Date:  1986

9.  Calcium metabolism in adult outpatients with epilepsy receiving long-term anticonvulsant therapy.

Authors:  G Pylypchuk; D G Oreopoulos; D R Wilson; J E Harrison; K G McNeill; H E Meema; R Ogilvie; W C Sturtridge; T M Murray
Journal:  Can Med Assoc J       Date:  1978-03-18       Impact factor: 8.262

Review 10.  Pharmacology and therapeutic use of vitamin D and its analogues.

Authors:  A M Pierides
Journal:  Drugs       Date:  1981-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.